Speaker Profile

Ph.D., Managing Executive, Personalized Science, LLC

Dr. Eric Lai is Managing Executive at Personalized Science, LLC and currently a team lead with the NIH COVID-19 Rapid Acceleration of Diagnostics (RADx) Initiative. For almost 30 years, Dr. Lai has focused his efforts in the clinical application of Pharmacogenomics in drug development and drug safety, from discovery to bedside. In 2002, Dr. Lai discovered the association of HLA5701 to the Abacavir hypersensitivity reaction. The Abacavir HLA5701 discovery significantly improved the benefit-risk relationship by identifying patients at high risk for a serious drug adverse reaction and is frequently quoted in FDA guidance as one of the most important demonstrations of genomic medicine.